NOT FOR RELEASE, DISTRIBUTION, PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

Ondine Biomedical Inc.
(“Ondine Biomedical” or the “Company”)

Ondine Biomedical announces AIM market listing

Ondine Biomedical (OBI:AIM) announces admission (“Admission”) of its Common Shares to the AIM Market of the London Stock Exchange. Canadian based Ondine has pioneered a new non-antibiotic antimicrobial technology called photodisinfection which rapidly destroys pathogens – including SARS-CoV-2 – without causing resistance.

Application has been made for admission to trading on the AIM market of the London Stock Exchange of 194,584,524 Common Shares. It is expected that admission will occur today at 8.00 a.m.

For further Information, contact:

Ondine Biomedical Inc.
Carolyn Cross, CEO                +1 604 669 0555

Arden Partners plc
Nominated Adviser and Broker           +44 (0)20 7614 5900
Ruari McGirr / Antonio Bossi

Vane Percy & Roberts
Financial PR
Simon Vane Percy                +44 (0) 1737 821891